A Phase I, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose and Multiple Dose Study of TT-00920 in Healthy Subjects
Latest Information Update: 01 Mar 2023
At a glance
- Drugs TT 00920 (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors TransThera Biosciences
Most Recent Events
- 24 Feb 2023 Status changed from recruiting to completed.
- 05 May 2022 New trial record